NCT01117311|CompletedResults
Vagal Nerve Stimulation and Glucose Metabolism
The Effect of Vagal Nerve Stimulation on Enteroendocrine Secretion and Glucose Metabolism
Loading search results
The Effect of Vagal Nerve Stimulation on Enteroendocrine Secretion and Glucose Metabolism
Sponsor study identifier
Secondary identifiers
NIH
NIH
interventional
9
1 country
1
Study Start
March 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2012
Actual (reported)Study Completion
November 2012
Actual (reported)The overall aim of this application is to determine the mechanism(s) by which common bariatric surgical procedures alter carbohydrate metabolism. The study proposed will examine the effect of vagal nerve stimulation on insulin secretion and action.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2012
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 4, 2010
Actual (reported)May 5, 2010
Actual (reported)March 2011
Date type not reportedThis date has not been verified as actual or estimated.
June 2012
Actual (reported)November 2012
Actual (reported)January 6, 2014
Actual (reported)Disposition Index
Total Disposition Index (DI) is a calculated value which represents the ability of a person's pancreas to lower blood glucose. A higher number means the pancreas is better able to lower blood glucose and a lower number means the pancreas is less able to lower blood glucose.
baseline, 2 weeks
Gastric Emptying Half-time
approximately 2 hours after radiolabeled meal is ingested
Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).
Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).
The implanted Vagal Nerve Blocker will be on at the time of study.
The implanted Vagal Nerve Blocker will be off at the time of study.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Adrian Vella, MD
Mayo Clinic
9 participants (actual enrollment reported by the registry).
First Submitted
May 4, 2010
First Posted
May 5, 2010
Study Start
March 2011
Date type not reportedThis date has not been verified as actual or estimated.
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Primary Completion
June 2012
Actual (reported)Study Completion
November 2012
Actual (reported)Last Updated
January 6, 2014
Results First Posted
January 6, 2014
Record last verified: 2013-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: